QHSLab, Inc. Reports Record Revenue Growth and Positive Net Income in Preliminary Q4 and FY 2024 Financial Results
Rhea-AI Summary
QHSLab Inc. (OTCQB: USAQ) reported strong preliminary, unaudited financial results for Q4 and FY 2024. Q4 revenue increased 98% year-over-year to $625,981, with gross margin expanding to 65.8%. The company achieved net income of $40,838 in Q4, compared to a net loss of $86,627 in Q4 2023.
For full-year 2024, revenue grew 51% to $2.1 million, with improved gross margin of 63.7%. The company recorded its first profitable year with net income of $69,188, compared to a loss of $468,362 in 2023. Cash flow from operations was $247,317, resulting in net positive cash flow of $105,586. The company strengthened its balance sheet by repaying $298,531 in loans.
Positive
- Revenue growth of 98% YoY in Q4 2024 to $625,981
- Full-year revenue increase of 51% to $2.1 million
- Gross margin improvement to 65.8% in Q4 and 63.7% for full year
- First profitable year with net income of $69,188
- Positive operating cash flow of $247,317
- Debt reduction of $298,531
Negative
- None.
News Market Reaction – USAQ
On the day this news was published, USAQ declined 10.71%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
- Four consecutive quarters of year-over-year revenue growth underscore continued business momentum.
- Revenue surges
98% in Q4 2024 compared to Q4 2023, marking a milestone year for QHSLab. - Operational efficiencies and strategic execution drive first profitable year.
WEST PALM BEACH, FL, Feb. 18, 2025 (GLOBE NEWSWIRE) -- QHSLab Inc. (the “Company”) (OTCQB: USAQ), a digital health company advancing personalized medicine through innovative population health screening and point of care diagnostic tools in primary care, today announced its preliminary, unaudited financial results for the fourth quarter and fiscal year ended December 31, 2024.
For the full year 2024, the Company recorded record revenue growth, substantial gross margin improvements, its first-ever year of profitability on a GAAP basis and positive cash flow from operations, which enabled it to repay a portion of its outstanding debt strengthening its balance sheet.
Financial Highlights:
- Fourth Quarter 2024 Preliminary Financial Results:
- Revenue surged
98% year-over-year to$625,981 , compared to$315,020 in Q4 2023, marking four consecutive quarters of year-over-year revenue growth. - Gross profit increased
117% to$412,154 , with gross margin expanding to65.8% , up from60.3% in the prior-year quarter. - Net income for Q4 2024 of
$40,838 , a significant improvement from a net loss of$86,627 in Q4 2023.
- Revenue surged
- Full-Year 2024 Preliminary Financial Results:
- Revenue grew
51% year-over-year, reaching$2.1 million compared to$1.4 million for the full-year 2023. - Gross margin improved to
63.7% , reflecting an enhanced product mix and increased operational efficiencies. - The Company recorded net income of
$69,188 for 2024, compared to a net loss of$468,362 in 2023, underscoring QHSLab’s strong financial momentum and commitment to profitable operations. - Positive Cash Flow Generation: The Company reported net positive cash flow of
$105,586 , driven by$247,317 in cash flow from operations, reflecting strong business performance. This was partially offset by a$141,731 net cash outflow from financing activities, which includes debt repayments and other financial obligations. - Continued Debt Reduction: The Company repaid
$298,531 in loans, further strengthening its balance sheet and reducing financial liabilities, reinforcing its commitment to long-term financial stability.
- Revenue grew
Management Commentary:
“These outstanding financial results reflect the continued execution of our strategic initiatives and the growing adoption of our digital medicine solutions,” said Troy Grogan, President and CEO of QHSLab. “We are thrilled to report
Audit Status and Future Outlook:
The Company is currently finalizing its independent year-end audit in preparation for filing its Annual Report on Form 10-K prior to the 2024 SEC reporting deadline. While these financial results remain unaudited and are subject to change, management is confident in the reported numbers and expects only minor adjustments, if any.
“We look forward to sharing our fully audited results in the coming weeks and remain committed to delivering strong financial performance and value to our shareholders,” added Troy Grogan. “With our continued expansion and operational efficiencies, we are excited about the future of QHSLab as we build on this momentum into 2025.”
For more information about QHSLab and our healthcare solutions, please visit www.qhslab.com.
About QHSLab, Inc.
QHSLab, Inc. (OTCQB: USAQ) is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. Digital healthcare allows doctors to assess patient responses quickly and effectively using advanced artificial intelligence algorithms. Digital healthcare can also remotely monitor patients’ vital signs and evaluate the effects of prescribed medicines and treatments on patients’ health through real-time data transferred from patient to doctor. QHSLab, Inc. also markets and sells point-of-care, rapid-response diagnostic tests used in the primary care practice. QHSLab, Inc.’s products and services are designed to help physicians improve patient monitoring and medical care while also increasing their revenues.
Forward-Looking Statements
Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may,’ ‘could,’ ‘believes,’ ‘estimates,’ ‘targets,’ ‘expects,’ or ‘intends,’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investor Relations Contact:
Brett Maas, Managing Principal, Hayden IR, LLC
brett@haydenir.com
646-536-7331
https://twitter.com/QHSLabInc
FAQ
What was USAQ's revenue growth in Q4 2024?
How much debt did USAQ repay in 2024?
What was USAQ's net income for full-year 2024?
What was USAQ's gross margin in Q4 2024?
How much operating cash flow did USAQ generate in 2024?
